• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Research's 100th Annual Meeting

Posted on: Tuesday, 14 April 2009, 07:00 CDT

-- Phase 1 Data from Colorectal Cancer and Oral Picoplatin Trials To Be Presented --

SOUTH SAN FRANCISCO, Calif., April 14 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company will present final data from two Phase 1 clinical trials of picoplatin, the Company's lead product candidate, at poster sessions during the American Association for Cancer Research 100th Annual Meeting 2009 at the Colorado Convention Center in Denver. The Company will present efficacy and safety data from its Phase 1 trial of picoplatin in colorectal cancer (CRC) and bioavailability data from its Phase 1 trial of an oral formulation of picoplatin.

Details are as follows: A Phase 1 study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) for colorectal cancer (CRC): Comparison of two picoplatin schedules Abstract #3578 Earhart R, Gladkov OA, Cheporov SV, Biakhov MY, Manikhas B, Berdov B, Tjulandin S, Breitz H, De Jager R. Tuesday, April 21, 8:00 a.m. MDT Clinical Research 11 Session Hall B-F, Poster Section 30 A Phase 1 randomized crossover oral picoplatin bioavailability pharmacokinetics and pharmacodynamics study Abstract #3594 Phillips A, Saleh M, Yee L, Sharma S, Houston S, Karlin D, Breitz H, DeJager R, Earhart R. Tuesday, April 21, 8:00 a.m. MDT Clinical Research 12 Hall B-F, Poster Section 31

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic 2 colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit

http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

SOURCE Poniard Pharmaceuticals, Inc.

Source: PR Newswire

More News in this Category